Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 7/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | THRB | P10828 | 4/20 | 0.41 |
| ▸ | TP53 | P04637 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7094558 | 0.69 | ALDH1A1 (0.40) | TSHRKMT2AMEN1THRBTP53 | |
| SCHEMBL15302068 | 0.63 | TSHR (1.00) | HPGDTSHRMAPTKMT2AMEN1 | |
| SCHEMBL20219039 | 0.63 | TSHR (0.76) | HPGDTSHRMAPTKMT2AMEN1 | |
| SCHEMBL4003248 | 0.62 | HPGD (0.53) | HPGDTSHRMAPTKMT2AMEN1 | |
| SCHEMBL21312832 | 0.62 | MAPT (0.73) | HPGDTSHRMAPTTP53 | |
| SCHEMBL4002460 | 0.61 | TSHR (0.73) | HPGDTSHRMAPTKMT2AMEN1 | |
| SCHEMBL31023418 | 0.61 | TSHR (0.73) | HPGDTSHRMAPTKMT2AMEN1 | |
| SCHEMBL26498838 | 0.61 | HPGD (0.72) | HPGDTSHRMAPTKMT2AMEN1 | |
| SCHEMBL10032004 | 0.60 | TSHR (0.71) | HPGDTSHRMAPTKMT2AMEN1 | |
| SCHEMBL7933287 | 0.60 | TSHR (0.71) | HPGDTSHRMAPTKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030229094-A1 | Acetamides and benzamides that are useful in treating sexual dysfunction | ABBOTT LABORATORIES | 2003-12-11 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229094-A1 | Acetamides and benzamides that are useful in treating sexual dysfunction | CATSPER1, CYP19A1, PDE12 | HPGD 375/4885TSHR 4192/4885MAPT 3896/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.